Video

Dr. Frankfurt on the Future of AML Treatments

Author(s):

Olga Frankfurt, MD

Olga Frankfurt, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the future of acute myeloid leukemia (AML) treatments.

Olga Frankfurt, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the future of acute myeloid leukemia (AML) treatments.

Recent FDA-approved agents are being used in a variety of combinations and settings, explains Frankfurt. For example, a BCL-2 inhibitor is currently being studied in combination with hypomethylating agents, decitabine and azacitidine, as well as low-dose cytarabine to treat patients with AML.

PD-1 inhibitors are also being used in combinations to treat leukemia and myelodysplastic syndrome.

Related Videos
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Related Content
Christopher Graham, MD, of University of Minnesota Medical School
January 10th 2025

Axatilimab Shakes Up cGVHD Treatment and Looks to Move to Earlier Line in Paradigm

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

NCCN: Image by Kellie Ehrmann/MJH Life Sciences using AI
December 31st 2024

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

OncLive’s December Roundup of Key FDA Approvals in Oncology
December 30th 2024

OncLive’s December Roundup of Key FDA Approvals in Oncology

Guillermo Garcia-Manero, MD
December 29th 2024

Paying It Forward: The Importance of Mentorship in a Medical Career